A Medical Device Daily

Vasomedical (Westbury, New York) reported that it has received a U.S. patent for technology that automatically controls and maintains the inflation and deflation pressures within the cuffs during enhanced external counterpulsation (EECP) therapy.

The patent also provides for a method to automatically release all applied pressure to the atmosphere in the event of a system or power failure as a safety measure to avoid injury to the patient.

At the start of treatment, the therapist selects the optimal inflation pressure for the patient to comfortably receive effective therapy; the technology then fully controls and maintains, with accuracy, the proper inflation and deflation pressures throughout the treatment.

“Control and maintenance of optimal pressure during EECP treatment is essential to the effectiveness of this therapy for the high percentage of patients that may have irregular or premature heart beats,” said Dr. John Hui, president/CEO of Vasomedical and inventor of the patent. Hui added: “The methods covered by this patent have been engineered into our current TS4 and Lumenair models. Vasomedical will continue to develop intellectual properties in its drive to produce the best quality products for the benefit of patients suffering from cardiovascular disease, further demonstrating Vasomedical’s leadership position in the noninvasive treatment arena and its commitment to increase shareholder value.”

EECP therapy is a noninvasive, outpatient therapy used to manage chronic stable angina and heart failure.